- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05401929
Transcranial Magnetic Brain Stimulation to Reduce Cannabis Use in Heavy Cannabis Users
Imaging the Effects of Intermittent Thetaburst Stimulation on Cannabis Self-Administration in Heavy Cannabis Users
The growing legalization of cannabis across the U.S. is associated with increases in cannabis use, and accordingly, an increase in the number of individuals with cannabis use problems, including cannabis use disorder (CUD). While there are several medications being investigated as treatment options for CUD, none have been FDA-approved, and there is limited efficacy of traditional behavioral therapy approaches for this population. Consequently, there is a pressing need for the development of new treatments, including approaches that specifically target the brain areas associated with problematic cannabis use behaviors. Elevated attention to drug cues is one of the primary causes of relapse in heavy cannabis users. Preliminary data suggests that transcranial magnetic stimulation (TMS), a non-invasive form of brain stimulation, may be a novel brain-based tool to decrease heightened attention to drug cues in people with CUD. Building on prior data, the primary goal of this study is to evaluate the feasibility and effectiveness of TMS as a tool to decrease attention to drug cues and reduce cannabis use.
This study will evaluate whether 2 weeks of rTMS can be used to decrease attentional bias to cannabis cues and reduce cannabis use in heavy cannabis users. We will recruit sixty (60) non-treatment seeking, near-daily cannabis users to receive 10 daily sessions of either real or sham (aka placebo) rTMS over a 2-week period. Participants will live on a residential research unit for 3 weeks. During the residential stay, data on cannabis use (measured using standard human laboratory measures of choice to smoke cannabis) and relevant brain activity (measured using drug cue exposure fMRI tasks) will be collected before and after the course of 10 daily rTMS sessions. We will aim to show whether real rTMS treatment reduces brain response and attentional bias to cannabis cues and reduces cannabis use levels.
Study Overview
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Tonisha Kearney-Ramos, PhD
- Phone Number: 646-774-6185
- Email: tonisha.kearney-ramos@nyspi.columbia.edu
Study Locations
-
-
New York
-
New York, New York, United States, 10032
- New York State Psychiatric Institute
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Males/non-pregnant females, 18-60 years old
- Current cannabis user
- Able to perform all study procedures
Exclusion Criteria:
- Use of other illicit drugs
- If medical history, physical and psychiatric examination, or laboratory tests performed during the screening process reveal any significant illness that the study physician deems contraindicated for study participation
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Active
|
Six trains of active intermittent thetaburst stimulation (iTBS) using neuronavigation-guided cortical targeting to the left dorsolateral prefrontal cortex location using figure-of-8 TMS coils.
Other Names:
Six trains of sham intermittent thetaburst stimulation (iTBS) using neuronavigation-guided cortical targeting to the left dorsolateral prefrontal cortex location using figure-of-8 TMS coils.
|
Sham Comparator: Sham
|
Six trains of active intermittent thetaburst stimulation (iTBS) using neuronavigation-guided cortical targeting to the left dorsolateral prefrontal cortex location using figure-of-8 TMS coils.
Other Names:
Six trains of sham intermittent thetaburst stimulation (iTBS) using neuronavigation-guided cortical targeting to the left dorsolateral prefrontal cortex location using figure-of-8 TMS coils.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Cannabis self-administration (laboratory)
Time Frame: Baseline (Inpatient Day 3), approx. half-way (Inpatient Day 10), and 2 weeks (Inpatient Day 18)
|
During the inpatient phase, there will be three cannabis self-administration sessions: one 1 day before the intermittent thetaburst stimulation (iTBS) intervention begins, one on inpatient day 10, and one 1 day after the full 10-day course of iTBS treatment.
On cannabis self-administration days, participants will be given 6 opportunities throughout the day at 1.5-h intervals (start at 9 am) to purchase 0-6 puffs of a cannabis cigarette from their study earnings, up to 36 puffs per day.
For each participant, we will quantify the total number of puff choices (0-36) they made to self-administer cannabis on Inpatient Day 3 (baseline; 1 day before the iTBS treatment) and compare it to Inpatient Day 18 (follow-up; 1 day after the full course of iTBS treatment).
|
Baseline (Inpatient Day 3), approx. half-way (Inpatient Day 10), and 2 weeks (Inpatient Day 18)
|
Change in Salience Network drug cue reactivity [functional brain data during Cannabis Stroop functional magnetic resonance imaging (fMRI) task]
Time Frame: Baseline (Inpatient Day 2) and 2.5 weeks (Inpatient Day 19)
|
Relative brain activity to cannabis vs neutral visual stimuli will be assessed during the Cannabis Stroop fMRI task from the first (baseline) to the last (2.5 weeks) timepoint.
|
Baseline (Inpatient Day 2) and 2.5 weeks (Inpatient Day 19)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to first cannabis use (outpatient)
Time Frame: Post-inpatient Outpatient Days 1 - 14
|
The outcome will be 'time to first use' of cannabis, which is the time latency (in days) until the first day that the participant endorses using cannabis during the post-inpatient outpatient EMA period (which occurs on Days 1-14 after inpatient discharge).
Endorsing the use of cannabis is given by a participant responding "Yes" to the daily Yes/No prompts sent via mobile phone each evening at 10pm which ask if they have used cannabis that day/timeframe.
|
Post-inpatient Outpatient Days 1 - 14
|
Change in Frequency of cannabis use (outpatient)
Time Frame: Baseline (Pre-Inpatient) Outpatient Days 1 - 14 and Post-inpatient Outpatient Days 1 - 14
|
The outcome will be 'frequency of cannabis use,' which is the total number of days/week during the 2-week post-inpatient outpatient EMA period that a participant endorses using cannabis (by responding "Yes" to the daily evening mobile phone prompt asking them if they used cannabis that day; daily prompts occur on Days 1-14 after inpatient discharge.
The frequency of use (total # of days/week used during the 2-week outpatient period) is computed independently for the pre-inpatient (baseline) and post-inpatient (follow-up) outpatient periods, and then the follow-up period is compared relative to baseline to get a measure of change following iTBS treatment.
|
Baseline (Pre-Inpatient) Outpatient Days 1 - 14 and Post-inpatient Outpatient Days 1 - 14
|
Change in Quantity of cannabis use (outpatient)
Time Frame: Baseline (Pre-Inpatient) Outpatient Days 1 - 14 and Post-inpatient Outpatient Days 1 - 14
|
The outcome will be 'quantity of cannabis use' which is the total number of grams during each 14-day outpatient period that a participant endorses using (by responding "Yes" to the mobile phone prompt asking them if they used cannabis that day, and then entering the quantity in the following mobile phone prompt asking them "How many total grams did you use?"
The quantity (total # of grams used over the 14-day period) is computed independently for the pre-inpatient (baseline) and post-inpatient (follow-up) outpatient periods, then the follow-up period is compared relative to baseline.
|
Baseline (Pre-Inpatient) Outpatient Days 1 - 14 and Post-inpatient Outpatient Days 1 - 14
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Tonisha Kearney-Ramos, PhD, New York State Psychiatric Institute
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
- treatment
- functional magnetic resonance imaging
- functional neuroimaging
- cannabis
- intervention
- repetitive transcranial magnetic stimulation
- marijuana
- double blind
- transcranial magnetic stimulation
- ecological momentary assessment
- intermittent theta burst stimulation
- inpatient
- randomized controlled clinical trials
- functional brain imaging
- attentional bias
- randomized clinical trials
- neuronavigation
- sham
- sham controlled
- self administration
- cannabis smoking
- marijuana smoking
- recreational marijuana use
- stroop task
- drug cue reactivity
- residential
- personalized cortical targeting
- biomarker development
- brain mapping
- neuroendophenotypes
- neurobiomarkers
Additional Relevant MeSH Terms
Other Study ID Numbers
- 8152
- 1K01DA050691-01A1 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cannabis
-
Centre hospitalier de l'Université de Montréal...RecruitingCannabis | Cannabis Dependence | Cannabis Use | Cannabis Smoking | Cannabis Use, UnspecifiedCanada
-
Elias DakwarRecruitingAddiction | Cannabis Dependence | Cannabis Use | Substance Abuse | Cannabis Abuse | Cannabis Use DisorderUnited States
-
University College, LondonMedical Research Council; InvicroCompletedCannabis | Cannabis Dependence | Cannabis Use | CBD | Adolescent Development | THC | Marijuana | Cannabis IntoxicationUnited Kingdom
-
University of WashingtonNational Institute on Drug Abuse (NIDA)CompletedCannabis Dependence | Cannabis Abuse
-
The University of Tennessee, KnoxvilleColorado State UniversityActive, not recruitingCannabis Use Disorder, Mild | Cannabis Use Disorder, Moderate | Cannabis Use Disorder, SevereUnited States
-
Assistance Publique - Hôpitaux de ParisTerminatedCannabis Dependence | Cannabis AbuseFrance
-
University of VermontDartmouth College; Rutgers UniversityCompletedCannabis Use | Tolerance | Cannabis WithdrawalUnited States
-
Medical University of South CarolinaNational Institute on Drug Abuse (NIDA); National Institutes of Health (NIH)Completed
-
Medical University of South CarolinaNational Institute on Drug Abuse (NIDA)RecruitingCannabis Use Disorder, Mild | Cannabis Use Disorder, Moderate | Cannabis Use Disorder, SevereUnited States
-
Yale UniversityRobert E. Leet and Clara Guthrie Patterson Trust Mentored Research AwardRecruitingCannabis | Cannabis Use | Cannabis AbuseUnited States
Clinical Trials on iTBS
-
Central South UniversityRecruitingSuicidal Ideation | Suicide and Self-harm | Non Suicidal Self InjuryChina
-
Changping LaboratoryChina Rehabilitation Research CenterRecruiting
-
Central South UniversityRecruitingBipolar Depression | Major Depressive DisorderChina
-
Centre for Addiction and Mental HealthUniversity Health Network, Toronto; University of British ColumbiaRecruiting
-
Medical University of South CarolinaMUSC Center for Biomedical Research Excellence in Stroke RecoveryCompleted
-
University Hospital, BonnUnknownPost Traumatic Stress Disorder | Intrusive ThoughtsGermany
-
Changping LaboratoryHenan Provincial People's HospitalNot yet recruitingAutism Spectrum Disorder
-
Changping LaboratoryChina Rehabilitation Research CenterRecruiting
-
Chang Gung Memorial HospitalActive, not recruitingDepressive Disorder, Treatment-ResistantTaiwan
-
China Medical University HospitalNational Science Council, TaiwanWithdrawnParkinson's Disease | Parkinson's Disease With Freezing of GaitTaiwan